Castle Biosciences
CSTL
185 hedge funds and large institutions have $737M invested in Castle Biosciences in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 76 increasing their positions, 47 reducing their positions, and 16 closing their positions.
844% more call options, than puts
Call options by funds: $8.7M | Put options by funds: $921K
163% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 16
62% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 47
34% more capital invested
Capital invested by funds: $549M → $737M (+$187M)
16% more funds holding
Funds holding: 159 → 185 (+26)
1.68% more ownership
Funds ownership: 91.41% → 93.09% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.3M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.52M |
| 3 |
SAM
Silvercrest Asset Management
New York
|
+$5.14M |
| 4 |
Renaissance Technologies
New York
|
+$4.79M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$21.8M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$16.1M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$12.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.35M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.87M |
CSTL Hedge Fund Activity: Q3 2024 in Review
185 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2024, worth a combined $737M — up 34% from $549M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CSTL positions and 16 closed out — a net gain of 26 holders — while 76 added to existing stakes and 47 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $11.3M. The largest seller was Deerfield Management, cutting an estimated $21.8M.
- 185 institutional investors held Castle Biosciences (CSTL) as of Q3 2024, up from 159 in Q2 2024.
- Funds reported $737M of Castle Biosciences stock for Q3 2024, up 34% quarter-over-quarter.
- 42 funds opened new Castle Biosciences positions in Q3 2024 and 16 closed out, a net change of +26 holders.
- The largest Castle Biosciences buyer in Q3 2024 was Point72 Asset Management, an estimated $11.3M added.
- The largest Castle Biosciences seller in Q3 2024 was Deerfield Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2024.